tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2015 Jul 1. pii: CVI.00736-14. [Epub ahead of print]
[h=1]The carbomer-lecithin adjuvant Adjuplex? has potent immune activating properties and elicits protective adaptive immunity against influenza challenge in mice.[/h] Wegmann F[SUP]1[/SUP], Moghaddam AE[SUP]2[/SUP], Schiffner T[SUP]2[/SUP], Gartlan KH[SUP]2[/SUP], Powell TJ[SUP]3[/SUP], Russell RA[SUP]2[/SUP], Baart M[SUP]4[/SUP], Carrow EW[SUP]5[/SUP], Sattentau QJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continuing discovery and development of adjuvants for vaccine formulation is important to safely increase potency and/or reduce antigen dose of existing vaccines, and tailor the adaptive immune response to newly-developed vaccines. Adjuplex? is a novel adjuvant platform based on purified lecithin and carbomer homopolymer. Here we analyzed the adjuvant activity of Adjuplex? in mice for the soluble hemagglutinin (HA) glycoprotein of influenza A. Titration of Adjuplex? revealed an optimal dose of 1% for immunogenicity, eliciting high titers of HA-specific HA, but inducing no significant weight loss. At this dose, Adjuplex? completely protected mice from an otherwise lethal influenza challenge, and was at least as effective as adjuvants MPL and alum in preventing disease. Adjuplex? elicited a balanced Th1/Th2-type immune response with accompanying cytokines, and triggered antigen-specific CD8[SUP]+[/SUP] T cell proliferation. Use of the peritoneal inflammation model revealed that Adjuplex? recruited dendritic cells (DCs), monocytes and neutrophils in the context of innate cytokine and chemokine secretion. Adjuplex? neither triggered classical maturation of DCs nor activated a pathogen recognition receptor (PRR)-expressing NFκB reporter cell line, suggesting a mechanism of action different from that reported for classical pathogen-associated molecular pattern (PAMP)-activated innate immunity. Taken together, these data reveal Adjuplex? as a potent and well-tolerated adjuvant with application for subunit vaccines.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26135973 [PubMed - as supplied by publisher]
[h=1]The carbomer-lecithin adjuvant Adjuplex? has potent immune activating properties and elicits protective adaptive immunity against influenza challenge in mice.[/h] Wegmann F[SUP]1[/SUP], Moghaddam AE[SUP]2[/SUP], Schiffner T[SUP]2[/SUP], Gartlan KH[SUP]2[/SUP], Powell TJ[SUP]3[/SUP], Russell RA[SUP]2[/SUP], Baart M[SUP]4[/SUP], Carrow EW[SUP]5[/SUP], Sattentau QJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continuing discovery and development of adjuvants for vaccine formulation is important to safely increase potency and/or reduce antigen dose of existing vaccines, and tailor the adaptive immune response to newly-developed vaccines. Adjuplex? is a novel adjuvant platform based on purified lecithin and carbomer homopolymer. Here we analyzed the adjuvant activity of Adjuplex? in mice for the soluble hemagglutinin (HA) glycoprotein of influenza A. Titration of Adjuplex? revealed an optimal dose of 1% for immunogenicity, eliciting high titers of HA-specific HA, but inducing no significant weight loss. At this dose, Adjuplex? completely protected mice from an otherwise lethal influenza challenge, and was at least as effective as adjuvants MPL and alum in preventing disease. Adjuplex? elicited a balanced Th1/Th2-type immune response with accompanying cytokines, and triggered antigen-specific CD8[SUP]+[/SUP] T cell proliferation. Use of the peritoneal inflammation model revealed that Adjuplex? recruited dendritic cells (DCs), monocytes and neutrophils in the context of innate cytokine and chemokine secretion. Adjuplex? neither triggered classical maturation of DCs nor activated a pathogen recognition receptor (PRR)-expressing NFκB reporter cell line, suggesting a mechanism of action different from that reported for classical pathogen-associated molecular pattern (PAMP)-activated innate immunity. Taken together, these data reveal Adjuplex? as a potent and well-tolerated adjuvant with application for subunit vaccines.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26135973 [PubMed - as supplied by publisher]